Cornerstone Capital Management Holdings LLC. reduced its stake in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) by 6.8% during the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 55,869 shares of the biotechnology company’s stock after selling 4,100 shares during the period. Cornerstone Capital Management Holdings LLC.’s holdings in Ironwood Pharmaceuticals were worth $880,000 as of its most recent SEC filing.

A number of other institutional investors also recently made changes to their positions in the business. Ameritas Investment Partners Inc. increased its stake in Ironwood Pharmaceuticals by 5.8% in the second quarter. Ameritas Investment Partners Inc. now owns 11,821 shares of the biotechnology company’s stock valued at $223,000 after purchasing an additional 648 shares during the last quarter. Aperio Group LLC increased its stake in Ironwood Pharmaceuticals by 11.9% in the second quarter. Aperio Group LLC now owns 13,213 shares of the biotechnology company’s stock valued at $249,000 after purchasing an additional 1,410 shares during the last quarter. Amalgamated Bank increased its stake in Ironwood Pharmaceuticals by 9.0% in the second quarter. Amalgamated Bank now owns 17,280 shares of the biotechnology company’s stock valued at $326,000 after purchasing an additional 1,421 shares during the last quarter. Virtu KCG Holdings LLC increased its stake in Ironwood Pharmaceuticals by 10.3% in the second quarter. Virtu KCG Holdings LLC now owns 15,740 shares of the biotechnology company’s stock valued at $297,000 after purchasing an additional 1,470 shares during the last quarter. Finally, Legal & General Group Plc grew its position in shares of Ironwood Pharmaceuticals by 5.0% during the second quarter. Legal & General Group Plc now owns 47,773 shares of the biotechnology company’s stock worth $900,000 after acquiring an additional 2,265 shares during the last quarter.

In related news, CEO Peter M. Hecht sold 113,405 shares of Ironwood Pharmaceuticals stock in a transaction on Thursday, December 7th. The shares were sold at an average price of $15.12, for a total value of $1,714,683.60. Following the transaction, the chief executive officer now directly owns 4,696,917 shares in the company, valued at approximately $71,017,385.04. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Over the last quarter, insiders sold 115,769 shares of company stock worth $1,752,491. 7.63% of the stock is currently owned by insiders.

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) opened at $15.39 on Monday. The company has a current ratio of 4.87, a quick ratio of 4.86 and a debt-to-equity ratio of -22.31. The stock has a market cap of $2,300.00, a P/E ratio of -16.03 and a beta of 1.44. Ironwood Pharmaceuticals, Inc. has a 1 year low of $13.43 and a 1 year high of $19.94.

Ironwood Pharmaceuticals (NASDAQ:IRWD) last posted its quarterly earnings data on Thursday, November 2nd. The biotechnology company reported ($0.18) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.25) by $0.07. Ironwood Pharmaceuticals had a negative net margin of 48.89% and a negative return on equity of 645.22%. The firm had revenue of $86.80 million for the quarter, compared to analyst estimates of $73.59 million. During the same period last year, the firm posted ($0.18) EPS. Ironwood Pharmaceuticals’s quarterly revenue was up 31.3% on a year-over-year basis. research analysts predict that Ironwood Pharmaceuticals, Inc. will post -1.12 EPS for the current year.

A number of brokerages have recently issued reports on IRWD. BidaskClub lowered shares of Ironwood Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Thursday, December 7th. Mizuho lowered shares of Ironwood Pharmaceuticals from a “buy” rating to a “neutral” rating and lowered their target price for the stock from $20.00 to $16.00 in a research report on Wednesday, December 6th. Morgan Stanley restated a “hold” rating on shares of Ironwood Pharmaceuticals in a research report on Monday, December 4th. ValuEngine upgraded shares of Ironwood Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Wednesday, November 29th. Finally, Credit Suisse Group began coverage on shares of Ironwood Pharmaceuticals in a research report on Monday, November 27th. They set a “buy” rating and a $19.00 target price on the stock. Nine equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and a consensus target price of $17.88.

TRADEMARK VIOLATION NOTICE: “Ironwood Pharmaceuticals, Inc. (IRWD) Holdings Reduced by Cornerstone Capital Management Holdings LLC.” was first posted by TheOlympiaReport and is the property of of TheOlympiaReport. If you are viewing this piece on another website, it was illegally stolen and reposted in violation of U.S. & international copyright legislation. The original version of this piece can be viewed at https://theolympiareport.com/2017/12/25/ironwood-pharmaceuticals-inc-irwd-holdings-reduced-by-cornerstone-capital-management-holdings-llc.html.

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals, Inc is a biotechnology company. The Company is advancing product opportunities in areas of unmet need, including irritable bowel syndrome with constipation (IBS C), and chronic idiopathic constipation (CIC), hyperuricemia associated with uncontrolled gout, uncontrolled gastroesophageal reflux disease (uncontrolled GERD), and vascular and fibrotic diseases.

Institutional Ownership by Quarter for Ironwood Pharmaceuticals (NASDAQ:IRWD)

Receive News & Ratings for Ironwood Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ironwood Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.